| Nome |
# |
|
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014, file dd9e0c65-731c-1e9c-e053-3a05fe0a45ef
|
163
|
|
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV, file dd9e0c66-f79d-1e9c-e053-3a05fe0a45ef
|
84
|
|
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?, file dd9e0c67-09f3-1e9c-e053-3a05fe0a45ef
|
84
|
|
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates, file dd9e0c65-fba8-1e9c-e053-3a05fe0a45ef
|
81
|
|
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016, file dd9e0c65-8347-1e9c-e053-3a05fe0a45ef
|
68
|
|
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients., file dd9e0c67-351b-1e9c-e053-3a05fe0a45ef
|
63
|
|
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015, file dd9e0c66-d6b6-1e9c-e053-3a05fe0a45ef
|
61
|
|
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study, file dd9e0c66-f8ad-1e9c-e053-3a05fe0a45ef
|
58
|
|
Splenic abscesses as a first manifestation of Crohn's disease: A case report, file dd9e0c67-09fa-1e9c-e053-3a05fe0a45ef
|
57
|
|
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort, file dd9e0c67-131e-1e9c-e053-3a05fe0a45ef
|
56
|
|
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy, file dd9e0c66-d198-1e9c-e053-3a05fe0a45ef
|
54
|
|
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine
evidence from the Italian MASTER Cohort., file dd9e0c67-0c4d-1e9c-e053-3a05fe0a45ef
|
53
|
|
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file dd9e0c65-6a19-1e9c-e053-3a05fe0a45ef
|
52
|
|
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART, file dd9e0c65-8058-1e9c-e053-3a05fe0a45ef
|
51
|
|
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC, file dd9e0c66-1469-1e9c-e053-3a05fe0a45ef
|
51
|
|
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?, file dd9e0c66-f796-1e9c-e053-3a05fe0a45ef
|
51
|
|
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection, file dd9e0c69-1094-1e9c-e053-3a05fe0a45ef
|
50
|
|
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file dd9e0c67-0e8a-1e9c-e053-3a05fe0a45ef
|
49
|
|
Letter: chronic hepatitis C genotype 3 infection - still a hurdle toward a direct-acting anti-viral-induced HCV cure?, file dd9e0c67-3a3d-1e9c-e053-3a05fe0a45ef
|
48
|
|
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients, file dd9e0c63-e698-1e9c-e053-3a05fe0a45ef
|
47
|
|
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART, file dd9e0c65-6aa5-1e9c-e053-3a05fe0a45ef
|
47
|
|
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice, file dd9e0c67-2388-1e9c-e053-3a05fe0a45ef
|
47
|
|
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort., file dd9e0c69-97a4-1e9c-e053-3a05fe0a45ef
|
46
|
|
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia, file dd9e0c66-e975-1e9c-e053-3a05fe0a45ef
|
45
|
|
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy, file dd9e0c66-d6b8-1e9c-e053-3a05fe0a45ef
|
44
|
|
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment, file dd9e0c67-2543-1e9c-e053-3a05fe0a45ef
|
44
|
|
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort, file dd9e0c67-222e-1e9c-e053-3a05fe0a45ef
|
42
|
|
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio, file dd9e0c66-d20e-1e9c-e053-3a05fe0a45ef
|
33
|
|
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe, file 5284dd77-db10-40e2-b153-cbe6fcc2e8ac
|
10
|
|
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs?, file dd9e0c6a-c789-1e9c-e053-3a05fe0a45ef
|
10
|
|
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study., file dd9e0c63-8da8-1e9c-e053-3a05fe0a45ef
|
6
|
|
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen, file dd9e0c65-6651-1e9c-e053-3a05fe0a45ef
|
6
|
|
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study, file dd9e0c6a-8873-1e9c-e053-3a05fe0a45ef
|
6
|
|
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data, file dd9e0c6a-9239-1e9c-e053-3a05fe0a45ef
|
6
|
|
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years, file dd9e0c63-400c-1e9c-e053-3a05fe0a45ef
|
5
|
|
Localized 1H-MR spectroscopy for metabolic characterization of brain diffuse and focal lesions in HIV infected patients, file dd9e0c63-b2e4-1e9c-e053-3a05fe0a45ef
|
3
|
|
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study., file dd9e0c62-7bb9-1e9c-e053-3a05fe0a45ef
|
2
|
|
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011., file dd9e0c62-83bb-1e9c-e053-3a05fe0a45ef
|
2
|
|
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin., file dd9e0c62-8a0e-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c62-f873-1e9c-e053-3a05fe0a45ef
|
2
|
|
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort, file dd9e0c63-8ad4-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c63-e627-1e9c-e053-3a05fe0a45ef
|
2
|
|
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study, file dd9e0c65-df08-1e9c-e053-3a05fe0a45ef
|
2
|
|
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014, file dd9e0c66-d3c0-1e9c-e053-3a05fe0a45ef
|
2
|
|
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy, file dd9e0c67-254c-1e9c-e053-3a05fe0a45ef
|
2
|
|
Occurrence of Acute Pulmonary Embolism in COVID-19—A case series, file dd9e0c6b-0d3f-1e9c-e053-3a05fe0a45ef
|
2
|
|
null, file dd9e0c65-e5a4-1e9c-e053-3a05fe0a45ef
|
1
|
|
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage, file dd9e0c66-515c-1e9c-e053-3a05fe0a45ef
|
1
|
|
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus, file dd9e0c66-d18d-1e9c-e053-3a05fe0a45ef
|
1
|
|
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study, file dd9e0c66-d191-1e9c-e053-3a05fe0a45ef
|
1
|
|
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL, file dd9e0c66-e7b6-1e9c-e053-3a05fe0a45ef
|
1
|
|
The Revival of an “Old” Marker: CD4/CD8 Ratio, file dd9e0c66-e973-1e9c-e053-3a05fe0a45ef
|
1
|
|
Sofosbuvir-based regimens against an “easy” villain: HCV genotype 2, file dd9e0c66-e976-1e9c-e053-3a05fe0a45ef
|
1
|
|
Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A “turning-off” effect of liver inflammation?, file dd9e0c66-f0a7-1e9c-e053-3a05fe0a45ef
|
1
|
|
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents, file dd9e0c66-f271-1e9c-e053-3a05fe0a45ef
|
1
|
|
Brief Report: Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression, file dd9e0c66-f276-1e9c-e053-3a05fe0a45ef
|
1
|
|
Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR., file dd9e0c67-0a80-1e9c-e053-3a05fe0a45ef
|
1
|
|
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL, file dd9e0c67-0fc9-1e9c-e053-3a05fe0a45ef
|
1
|
|
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison, file dd9e0c67-2066-1e9c-e053-3a05fe0a45ef
|
1
|
|
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR, file dd9e0c67-237f-1e9c-e053-3a05fe0a45ef
|
1
|
|
The elderly and direct antiviral agents: Constraint or challenge?, file dd9e0c67-2693-1e9c-e053-3a05fe0a45ef
|
1
|
|
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals, file dd9e0c67-27fc-1e9c-e053-3a05fe0a45ef
|
1
|
|
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort)., file dd9e0c67-33cc-1e9c-e053-3a05fe0a45ef
|
1
|
|
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin, file dd9e0c6a-97ce-1e9c-e053-3a05fe0a45ef
|
1
|
|
Access to health services for undocumented immigrants in Apulia., file dd9e0c6b-108f-1e9c-e053-3a05fe0a45ef
|
1
|
|
Pulmonary Artery Filling Defects in Covid-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication?, file dd9e0c6b-8cf1-1e9c-e053-3a05fe0a45ef
|
1
|
| Totale |
1.721 |